

# ENB's advantage

ETBRi therapy targets multiple players in TME unlike many single target therapies under investigation

Safety advantage: ENB-003 with no toxicity at doses 250X higher than therapeutic window. No toxicities observed thus far in the Ph1 trial

Therapies on the horizon that target the TME still with significant non-responder rates and toxicity

Only 1 other company developing ETBRis\*-preclinical stage, significant FTO hurdles from our IP portfolio

There are no SoC treatments for the patient populations we are targeting

The logo for ENB Therapeutics, featuring the letters 'ENB' in a bold, stylized, blue font. The 'E' and 'B' are connected at the top, and the 'N' is positioned between them. The letters are set against a light blue circular background that is part of a larger graphic consisting of concentric arcs and a central circle.

ENB Therapeutics